Medicine and Dentistry
Adverse Event
5%
Adverse Outcome
7%
Albuminuria
50%
Angiotensin Receptor Antagonist
6%
Biological Marker
18%
Blood Pressure
11%
Canagliflozin
33%
Cardiovascular Disease
17%
Cardiovascular Risk
9%
Cardiovascular System
51%
Chronic Kidney Disease
69%
Clinical Trial
26%
Creatinine
33%
Dapagliflozin
24%
Diabetes
33%
Diabetes Mellitus
14%
Diabetic Nephropathy
30%
Disease
7%
Disease Exacerbation
14%
Empagliflozin
6%
End Stage Renal Disease
18%
Glomerular Filtration Rate
46%
Hazard Ratio
13%
Heart Failure
20%
Hemoglobin A1c
8%
Kidney Function
24%
Maturity Onset Diabetes of the Young
54%
Meta-Analysis
17%
Microalbuminuria
8%
Nephropathy
42%
Patient with Diabetes
5%
Patient with Type 2 Diabetes
32%
Placebo
31%
Population
5%
Post-Hoc Analysis
18%
Proportional Hazards Model
5%
Proteinuria
9%
Randomized Controlled Trial
10%
Renal Failure
19%
Renal Protection
7%
Renin Angiotensin Aldosterone System
11%
Sodium Glucose Cotransporter 2
5%
Sodium Glucose Cotransporter 2 Inhibitor
25%
Sodium Intake
7%
Systolic Blood Pressure
6%
Treatment Effect
9%
Urinary System
28%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
8%
Adverse Outcome
10%
Albuminuria
61%
Aldosterone
8%
All Cause Mortality
7%
Angiotensin
12%
Angiotensin Receptor Antagonist
13%
Atrasentan
14%
Biological Marker
17%
Brain Natriuretic Peptide
6%
Canagliflozin
34%
Cardiovascular Disease
14%
Cardiovascular Risk
10%
Chronic Kidney Failure
80%
Clinical Trial
33%
Creatinine
51%
Dapagliflozin
57%
Diabetes Mellitus
14%
Diabetic Nephropathy
34%
Dipeptidyl Carboxypeptidase Inhibitor
6%
Disease
9%
Disease Exacerbation
13%
Empagliflozin
10%
End Stage Renal Disease
20%
Endothelin Receptor Antagonist
7%
Exendin 4
5%
Glucagon Like Peptide 1 Receptor Agonist
5%
Heart Failure
25%
Hemoglobin A1c
10%
Irbesartan
5%
Kidney Disease
45%
Kidney Failure
21%
Losartan
7%
Microalbuminuria
8%
Non Insulin Dependent Diabetes Mellitus
100%
Placebo
49%
Proteinuria
6%
Randomized Clinical Trial
6%
Randomized Controlled Trial
13%
Renin
14%
Sodium Glucose Cotransporter 2
5%
Sodium Glucose Cotransporter 2 Inhibitor
34%
Keyphrases
Adverse Outcomes
9%
Albumin-to-creatinine Ratio
30%
Albuminuria
42%
Angiotensin Receptor Blockers
7%
Atrasentan
8%
Blood Pressure
5%
Canagliflozin
28%
CANVAS Program
5%
Cardiovascular Events
5%
Cardiovascular Mortality
9%
Cardiovascular Outcomes
18%
Chronic Kidney Disease
57%
Clinical Evaluation
7%
Clinical Trials
12%
Confidence Interval
15%
Credence
10%
Dapagliflozin
40%
Diabetes
14%
Diabetic Kidney Disease
25%
Diabetic Nephropathy
8%
Empagliflozin
5%
Estimated Glomerular Filtration Rate
27%
Estimated Glomerular Filtration Rate Decline
6%
Hazard Ratio
12%
Heart Failure
7%
Hemoglobin A1c (HbA1c)
5%
Hypertension
5%
Kidney
11%
Kidney Disease
6%
Kidney Disease Progression
11%
Kidney Failure
11%
Kidney Function
8%
Kidney Outcomes
15%
Meta-analysis
12%
Microalbuminuria
5%
Multiple Risk Factors
5%
Nephropathy
12%
Patients with Diabetes
6%
Placebo
21%
Proteinuria
6%
Randomized Controlled Trial
8%
Renal Events
10%
Renal Outcome
10%
Risk Markers
8%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
28%
Systolic Blood Pressure
5%
Treatment Effect
6%
Type 2 Diabetes Mellitus (T2DM)
39%
Type 2 Diabetic Patients
40%
Urinary Albumin Excretion
6%
